JP2018520642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520642A5 JP2018520642A5 JP2017557140A JP2017557140A JP2018520642A5 JP 2018520642 A5 JP2018520642 A5 JP 2018520642A5 JP 2017557140 A JP2017557140 A JP 2017557140A JP 2017557140 A JP2017557140 A JP 2017557140A JP 2018520642 A5 JP2018520642 A5 JP 2018520642A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 70
- 239000003814 drug Substances 0.000 claims 24
- 210000004027 cell Anatomy 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 9
- 125000005647 linker group Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 102100034845 KiSS-1 receptor Human genes 0.000 claims 6
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000011800 void material Substances 0.000 claims 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 5
- -1 MMP -8 Proteins 0.000 claims 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 108010023729 Complement 3d Receptors Proteins 0.000 claims 4
- 102000011412 Complement 3d Receptors Human genes 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 4
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 4
- 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 claims 4
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims 4
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims 4
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 claims 4
- 102000035195 Peptidases Human genes 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 4
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229940088598 enzyme Drugs 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 3
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 3
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims 3
- 102000005741 Metalloproteases Human genes 0.000 claims 3
- 108010006035 Metalloproteases Proteins 0.000 claims 3
- 102100023123 Mucin-16 Human genes 0.000 claims 3
- 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 2
- 102100024220 CD180 antigen Human genes 0.000 claims 2
- 108090000426 Caspase-1 Proteins 0.000 claims 2
- 102100035904 Caspase-1 Human genes 0.000 claims 2
- 102100024940 Cathepsin K Human genes 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 2
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 2
- 101710109241 E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 claims 2
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000001398 Granzyme Human genes 0.000 claims 2
- 108060005986 Granzyme Proteins 0.000 claims 2
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 2
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 claims 2
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 2
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 claims 2
- 101000958332 Homo sapiens Lymphocyte antigen 6 complex locus protein G6d Proteins 0.000 claims 2
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 claims 2
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 2
- 101000829779 Homo sapiens Probable G-protein coupled receptor 19 Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000825475 Homo sapiens Protein shisa-2 homolog Proteins 0.000 claims 2
- 101000604039 Homo sapiens Sodium-dependent phosphate transport protein 2B Proteins 0.000 claims 2
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 claims 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 claims 2
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 claims 2
- 102000052922 Large Neutral Amino Acid-Transporter 1 Human genes 0.000 claims 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 2
- 102100038210 Lymphocyte antigen 6 complex locus protein G6d Human genes 0.000 claims 2
- 101710112577 Multidrug resistance protein 4 Proteins 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- 102100023417 Probable G-protein coupled receptor 19 Human genes 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100022938 Protein shisa-2 homolog Human genes 0.000 claims 2
- 108091006232 SLC7A5 Proteins 0.000 claims 2
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 102100031228 Transient receptor potential cation channel subfamily M member 4 Human genes 0.000 claims 2
- 102000003425 Tyrosinase Human genes 0.000 claims 2
- 108060008724 Tyrosinase Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 210000004901 leucine-rich repeat Anatomy 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 235000019833 protease Nutrition 0.000 claims 2
- 235000019419 proteases Nutrition 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091007507 ADAM12 Proteins 0.000 claims 1
- 108091007505 ADAM17 Proteins 0.000 claims 1
- 108091005663 ADAMTS5 Proteins 0.000 claims 1
- 102000051389 ADAMTS5 Human genes 0.000 claims 1
- 102100025261 AMSH-like protease Human genes 0.000 claims 1
- 101710195537 AMSH-like protease Proteins 0.000 claims 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 101710129514 B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 108010003455 BLyS receptor Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010085074 Brevican Proteins 0.000 claims 1
- 102100032312 Brevican core protein Human genes 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 108010032088 Calpain Proteins 0.000 claims 1
- 102000007590 Calpain Human genes 0.000 claims 1
- 102000003900 Calpain-2 Human genes 0.000 claims 1
- 108090000232 Calpain-2 Proteins 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 102000004018 Caspase 6 Human genes 0.000 claims 1
- 108090000425 Caspase 6 Proteins 0.000 claims 1
- 108090000567 Caspase 7 Proteins 0.000 claims 1
- 102000004066 Caspase-12 Human genes 0.000 claims 1
- 108090000570 Caspase-12 Proteins 0.000 claims 1
- 102000004958 Caspase-14 Human genes 0.000 claims 1
- 108090001132 Caspase-14 Proteins 0.000 claims 1
- 102000004046 Caspase-2 Human genes 0.000 claims 1
- 108090000552 Caspase-2 Proteins 0.000 claims 1
- 102100029855 Caspase-3 Human genes 0.000 claims 1
- 102100025597 Caspase-4 Human genes 0.000 claims 1
- 101710090338 Caspase-4 Proteins 0.000 claims 1
- 102100038916 Caspase-5 Human genes 0.000 claims 1
- 101710090333 Caspase-5 Proteins 0.000 claims 1
- 102100038902 Caspase-7 Human genes 0.000 claims 1
- 102000004091 Caspase-8 Human genes 0.000 claims 1
- 108090000538 Caspase-8 Proteins 0.000 claims 1
- 102100026550 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 108010059081 Cathepsin A Proteins 0.000 claims 1
- 102000005572 Cathepsin A Human genes 0.000 claims 1
- 108090000712 Cathepsin B Proteins 0.000 claims 1
- 102000004225 Cathepsin B Human genes 0.000 claims 1
- 102000003908 Cathepsin D Human genes 0.000 claims 1
- 108090000258 Cathepsin D Proteins 0.000 claims 1
- 102000004178 Cathepsin E Human genes 0.000 claims 1
- 108090000611 Cathepsin E Proteins 0.000 claims 1
- 108090000610 Cathepsin F Proteins 0.000 claims 1
- 102000004176 Cathepsin F Human genes 0.000 claims 1
- 108090000619 Cathepsin H Proteins 0.000 claims 1
- 102000004175 Cathepsin H Human genes 0.000 claims 1
- 108090000625 Cathepsin K Proteins 0.000 claims 1
- 108090000624 Cathepsin L Proteins 0.000 claims 1
- 102000004172 Cathepsin L Human genes 0.000 claims 1
- 102100026540 Cathepsin L2 Human genes 0.000 claims 1
- 101710169274 Cathepsin L2 Proteins 0.000 claims 1
- 101710177066 Cathepsin O Proteins 0.000 claims 1
- 108090000613 Cathepsin S Proteins 0.000 claims 1
- 102100035654 Cathepsin S Human genes 0.000 claims 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 claims 1
- 102100027995 Collagenase 3 Human genes 0.000 claims 1
- 108050005238 Collagenase 3 Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100030886 Complement receptor type 1 Human genes 0.000 claims 1
- 206010054002 Congenital syphilitic osteochondritis Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 101800001224 Disintegrin Proteins 0.000 claims 1
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 claims 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108050001154 Glypican Proteins 0.000 claims 1
- 102000010956 Glypican Human genes 0.000 claims 1
- 108050007237 Glypican-3 Proteins 0.000 claims 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 102000004989 Hepsin Human genes 0.000 claims 1
- 108090001101 Hepsin Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 claims 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101100119857 Homo sapiens FCRL2 gene Proteins 0.000 claims 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims 1
- 101001008922 Homo sapiens Kallikrein-11 Proteins 0.000 claims 1
- 101001091379 Homo sapiens Kallikrein-5 Proteins 0.000 claims 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 claims 1
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 claims 1
- 101001038505 Homo sapiens Ly6/PLAUR domain-containing protein 1 Proteins 0.000 claims 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims 1
- 101000853730 Homo sapiens RING finger and transmembrane domain-containing protein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000832248 Homo sapiens STAM-binding protein Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 claims 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims 1
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims 1
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 102000001399 Kallikrein Human genes 0.000 claims 1
- 108060005987 Kallikrein Proteins 0.000 claims 1
- 102100027612 Kallikrein-11 Human genes 0.000 claims 1
- 102100034868 Kallikrein-5 Human genes 0.000 claims 1
- 102100034866 Kallikrein-6 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 claims 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 claims 1
- 102100040284 Ly6/PLAUR domain-containing protein 1 Human genes 0.000 claims 1
- 101710157879 Lymphocyte antigen 6E Proteins 0.000 claims 1
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 claims 1
- 102100030417 Matrilysin Human genes 0.000 claims 1
- 108090000855 Matrilysin Proteins 0.000 claims 1
- 108010091175 Matriptase Proteins 0.000 claims 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 claims 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 102100025096 Mesothelin Human genes 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims 1
- 101100182721 Mus musculus Ly6e gene Proteins 0.000 claims 1
- 101000623899 Mus musculus Mucin-13 Proteins 0.000 claims 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100034869 Plasma kallikrein Human genes 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 102000016611 Proteoglycans Human genes 0.000 claims 1
- 108010067787 Proteoglycans Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108010080192 Purinergic Receptors Proteins 0.000 claims 1
- 102000000033 Purinergic Receptors Human genes 0.000 claims 1
- 102100035928 RING finger and transmembrane domain-containing protein 2 Human genes 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000014400 SH2 domains Human genes 0.000 claims 1
- 108050003452 SH2 domains Proteins 0.000 claims 1
- 108091058557 SILV Proteins 0.000 claims 1
- 108091006576 SLC34A2 Proteins 0.000 claims 1
- 102100024472 STAM-binding protein Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 101710108790 Stromelysin-1 Proteins 0.000 claims 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102000003618 TRPM4 Human genes 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 102100026159 Tomoregulin-1 Human genes 0.000 claims 1
- 102100026160 Tomoregulin-2 Human genes 0.000 claims 1
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 241000269368 Xenopus laevis Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000000576 arachnoid Anatomy 0.000 claims 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 108010018550 caspase 13 Proteins 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 102000052502 human ELANE Human genes 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 108010047374 matriptase 2 Proteins 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108091007169 meprins Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 108010037277 thymic shared antigen-1 Proteins 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148459A JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗cd3抗体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155723P | 2015-05-01 | 2015-05-01 | |
| US62/155,723 | 2015-05-01 | ||
| PCT/US2016/030127 WO2016179003A1 (en) | 2015-05-01 | 2016-04-29 | Masked anti-cd3 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148459A Division JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗cd3抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520642A JP2018520642A (ja) | 2018-08-02 |
| JP2018520642A5 true JP2018520642A5 (cg-RX-API-DMAC7.html) | 2019-06-13 |
Family
ID=56072419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557140A Pending JP2018520642A (ja) | 2015-05-01 | 2016-04-29 | マスク抗cd3抗体及びその使用方法 |
| JP2021148459A Pending JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗cd3抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148459A Pending JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗cd3抗体及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180057593A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3778640A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018520642A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107709363A (cg-RX-API-DMAC7.html) |
| HK (2) | HK1250997A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016179003A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| CN110437337B (zh) | 2013-02-26 | 2024-07-30 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| SG11201704056XA (en) | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| JP6841754B2 (ja) | 2015-05-13 | 2021-03-10 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| JP7044700B2 (ja) | 2015-10-02 | 2022-03-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子 |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化t細胞二重特異性分子 |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| HRP20251020T1 (hr) | 2016-05-20 | 2025-10-24 | Harpoon Therapeutics, Inc. | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| CN109843926B (zh) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| KR102275008B1 (ko) | 2016-11-23 | 2021-07-13 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
| JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法 |
| AU2017364818C1 (en) | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| CA3041279A1 (en) | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding domain, and polypeptide including conveying section |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| US20200123256A1 (en) * | 2017-05-02 | 2020-04-23 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US20200115461A1 (en) * | 2017-05-03 | 2020-04-16 | Harpoon Therapeutics, Inc. | Compositions and methods for adoptive cell therapies |
| US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| WO2019036433A2 (en) | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION |
| CN111356700A (zh) | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| KR20250134208A (ko) | 2017-11-28 | 2025-09-09 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드 |
| KR20200089312A (ko) | 2017-11-28 | 2020-07-24 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| KR20260039804A (ko) | 2017-12-21 | 2026-03-20 | 아뮤닉스 파마슈티컬스, 인크. | 유리 세그먼트 및 이것을 포함하는 결합 조성물 |
| CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
| CN110218254B (zh) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb25及其制备方法与应用 |
| MX2020012217A (es) * | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| EA202092849A1 (ru) | 2018-05-24 | 2021-03-16 | Янссен Байотек, Инк. | Моноспецифические и мультиспецифические антитела к tmeff2 и их применение |
| EP3816182A4 (en) | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY |
| EP3807312A4 (en) | 2018-05-30 | 2022-07-20 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT |
| FI3817770T3 (fi) | 2018-07-02 | 2026-07-06 | Amgen Inc | Antigeeniä sitova anti-steap1-proteiini |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| WO2020084608A1 (en) * | 2018-10-22 | 2020-04-30 | Explore Bio 1 Ltd | Precursor bispecific antibody constructs and methods of use thereof |
| JP2022515152A (ja) * | 2018-12-19 | 2022-02-17 | シティ・オブ・ホープ | Baff-r二重特異性t細胞エンゲージャー抗体 |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| WO2020232303A1 (en) | 2019-05-14 | 2020-11-19 | Harpoon Therapeutics, Inc. | EpCAM BINDING PROTEINS AND METHODS OF USE |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| EP3981428A4 (en) | 2019-06-05 | 2023-07-12 | Chugai Seiyaku Kabushiki Kaisha | Protease substrate, and polypeptide including protease cleavage sequence |
| CN113905757B (zh) | 2019-06-05 | 2026-01-13 | 中外制药株式会社 | 抗体切割位点结合分子 |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Pd−1/cd3二重特異性タンパク質による血液がん治療 |
| CR20220330A (es) | 2019-12-13 | 2022-08-04 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso. |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
| CN115943210A (zh) | 2020-01-20 | 2023-04-07 | 中外制药株式会社 | 配体结合融合蛋白 |
| BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| WO2021207657A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CR20220637A (es) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19 |
| MX2023004299A (es) | 2020-10-13 | 2023-07-07 | Univ Pennsylvania | Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm. |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP4240493A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック, インコーポレイテッド | 抗cd20/抗cd3二重特異性抗体の皮下投薬 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重car-t組成物及び方法 |
| CN118878693A (zh) * | 2020-11-23 | 2024-11-01 | 康诺亚生物医药科技(成都)有限公司 | 一种双特异性抗体及其用途 |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| EP4319806A1 (en) * | 2021-04-06 | 2024-02-14 | Takeda Pharmaceutical Company Limited | Therapeutic methods using constrained conditionally activated binding proteins |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2023100829A1 (ja) * | 2021-11-30 | 2023-06-08 | 第一三共株式会社 | プロテアーゼ分解性マスク抗体 |
| JP2025512798A (ja) * | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス,インク. | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| US20240059790A1 (en) * | 2022-04-04 | 2024-02-22 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2024112867A1 (en) | 2022-11-23 | 2024-05-30 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
| CN116724057A (zh) * | 2022-11-28 | 2023-09-08 | 浙江时迈药业有限公司 | 蛋白酶可切割的重组双特异性抗体和组合物及其用途 |
| CN122094980A (zh) * | 2023-09-20 | 2026-05-26 | 进化免疫治疗公司 | 靶向cd180和cd3的双特异性抗体融合分子及其使用方法 |
| CN122341642A (zh) | 2023-09-21 | 2026-07-03 | 多曼治疗学公司 | 抗ccr8单克隆抗体及其治疗用途 |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2026136785A1 (en) * | 2024-12-19 | 2026-06-25 | Amgen Inc. | T cell engager masking molecules with reduced isomerization tendencies |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート |
| US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| PL2155788T3 (pl) * | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| SI2155788T1 (sl) * | 2007-04-03 | 2012-11-30 | Amgen Res Munich Gmbh | Bispecifični vezavni element specifičen za križane vrste |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| KR20110097772A (ko) * | 2008-11-17 | 2011-08-31 | 제넨테크, 인크. | 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제 |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| WO2012162067A2 (en) * | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| JP6407726B2 (ja) * | 2012-03-01 | 2018-10-24 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | 長寿命ポリペプチド結合分子 |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| SG11201509595PA (en) * | 2013-05-28 | 2015-12-30 | Dcb Usa Llc | Antibody locker for the inactivation of protein drug |
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
-
2016
- 2016-04-29 EP EP20184006.3A patent/EP3778640A1/en not_active Withdrawn
- 2016-04-29 CN CN201680031767.8A patent/CN107709363A/zh active Pending
- 2016-04-29 EP EP16724772.5A patent/EP3288981A1/en not_active Withdrawn
- 2016-04-29 HK HK18110392.3A patent/HK1250997A1/zh unknown
- 2016-04-29 HK HK18111551.8A patent/HK1252158A1/zh unknown
- 2016-04-29 JP JP2017557140A patent/JP2018520642A/ja active Pending
- 2016-04-29 WO PCT/US2016/030127 patent/WO2016179003A1/en not_active Ceased
-
2017
- 2017-10-19 US US15/787,922 patent/US20180057593A1/en not_active Abandoned
-
2021
- 2021-09-13 JP JP2021148459A patent/JP2022023031A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111601825B (zh) | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 | |
| CN112771066B (zh) | 可活化抗体及其制备和使用方法 | |
| CN107849136B (zh) | 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途 | |
| WO2023015169A1 (en) | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof | |
| CN113993540A (zh) | 用于治疗癌症的一种或多种包含靶向掩蔽i型干扰素(ifna和ifnb)和针对肿瘤抗原的抗体的融合蛋白组合物 | |
| WO2008101234A2 (en) | Anti ganglioside gd3 antibodies and uses thereof | |
| US12617866B2 (en) | Humanized antibodies to mucin-16 and methods of use thereof | |
| CN113227147B (zh) | 全人源的抗cd30单链抗体及其应用 | |
| US20220233709A1 (en) | Masked Antibody Formulations | |
| AU2006241099A1 (en) | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells | |
| JP7522482B2 (ja) | クローディン18.2の抗体及びその使用 | |
| JP2025160226A (ja) | Fc変異を有するヘテロダイマータンパク質 | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2022546572A5 (cg-RX-API-DMAC7.html) | ||
| CN114650843A (zh) | 包括fc突变和位点特异性缀合性质的抗体组合物 | |
| WO2024113099A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| EP4136122A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
| Emery et al. | Section Review: Humanised monoclonal antibodies for therapeutic applications | |
| CN114269784A (zh) | 具有选择性可切割接头的双特异性结合构建体 | |
| CN119137159A (zh) | 抗cd137抗体和其制备和使用方法 | |
| JP2024531338A (ja) | 活性化可能インターフェロンポリペプチド及びその使用方法 | |
| CN117529330A (zh) | 用于治疗癌症的包括所掩蔽的I型干扰素(IFNα和IFNβ)的融合蛋白组合物和其方法 | |
| WO2019173417A1 (en) | Anti-tip-1 antibodies and uses thereof | |
| CN116535509B (zh) | 抗CD79b抗体、其制备方法及其应用 | |
| WO2025165594A1 (en) | Anti-pd-l1 and il-15 prodrug bifunctional protein and uses thereof |